3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis

Carmela Gurrieri, Francesco Piazza, Marianna Gnoato, Barbara Montini, Lucia Biasutto, Cristina Gattazzo, Enrico Brunetta, Anna Cabrelle, Francesco Cinetto, Raffaele Niero, Monica Facco, Spiridione Garbisa, Fiorella Calabrese, Gianpietro Semenzato, Carlo Agostini

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Glycogen synthase kinase (GSK)-3 modulates the production of inflammatory cytokines. Because bleomycin (BLM) causes lung injury, which is characterized by an inflammatory response followed by a fibrotic degeneration, we postulated that blocking GSK-3 activity with a specific inhibitor could affect the inflammatory and profibrotic cytokine network generated in the BLM-induced process of pulmonary inflammation and fibrosis. Thus, here we investigated the effects of the GSK-3 inhibitor 3-(2,4-dichlorophenyl)-4-(1-methyl-1Hindol-3-yl)- 1H-pyrrole-2,5-dione (SB216763) on a BLMinduced lung fibrosis model in mice. SB216763 prevented lung inflammation and the subsequent fibrosis when coad-ministered with BLM. Bronchoalveolar lavage fluid analysis of mice treated with BLM plus SB216763 revealed a significant reduction in BLM-induced alveolitis. Furthermore, SB216763 treatment was associated with a significantly lower production of inflammatory cytokines by macrophages. BLM-treated mice that received SB216763 developed alveolar epithelial cell damage and pulmonary fibrosis to a significantly lower extent compared with BLM-treated controls. These findings suggest that GSK-3 inhibition has a protective effect on lung fibrosis induced by BLM and candidate GSK-3 as a potential therapeutic target for preventing pulmonary fibrosis.

Original languageEnglish
Pages (from-to)785-794
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume332
Issue number3
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Glycogen Synthase Kinase 3
Pulmonary Fibrosis
Bleomycin
Pneumonia
Fibrosis
Cytokines
Therapeutics
Clergy
Alveolar Epithelial Cells
Lung
Pyrroles
Bronchoalveolar Lavage Fluid
Lung Injury
SB 216763
Macrophages

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis. / Gurrieri, Carmela; Piazza, Francesco; Gnoato, Marianna; Montini, Barbara; Biasutto, Lucia; Gattazzo, Cristina; Brunetta, Enrico; Cabrelle, Anna; Cinetto, Francesco; Niero, Raffaele; Facco, Monica; Garbisa, Spiridione; Calabrese, Fiorella; Semenzato, Gianpietro; Agostini, Carlo.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 332, No. 3, 03.2010, p. 785-794.

Research output: Contribution to journalArticle

Gurrieri, C, Piazza, F, Gnoato, M, Montini, B, Biasutto, L, Gattazzo, C, Brunetta, E, Cabrelle, A, Cinetto, F, Niero, R, Facco, M, Garbisa, S, Calabrese, F, Semenzato, G & Agostini, C 2010, '3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis', Journal of Pharmacology and Experimental Therapeutics, vol. 332, no. 3, pp. 785-794. https://doi.org/10.1124/jpet.109.153049
Gurrieri, Carmela ; Piazza, Francesco ; Gnoato, Marianna ; Montini, Barbara ; Biasutto, Lucia ; Gattazzo, Cristina ; Brunetta, Enrico ; Cabrelle, Anna ; Cinetto, Francesco ; Niero, Raffaele ; Facco, Monica ; Garbisa, Spiridione ; Calabrese, Fiorella ; Semenzato, Gianpietro ; Agostini, Carlo. / 3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis. In: Journal of Pharmacology and Experimental Therapeutics. 2010 ; Vol. 332, No. 3. pp. 785-794.
@article{1f4bcbe1f09b4090b0c9387e0112a7cc,
title = "3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis",
abstract = "Glycogen synthase kinase (GSK)-3 modulates the production of inflammatory cytokines. Because bleomycin (BLM) causes lung injury, which is characterized by an inflammatory response followed by a fibrotic degeneration, we postulated that blocking GSK-3 activity with a specific inhibitor could affect the inflammatory and profibrotic cytokine network generated in the BLM-induced process of pulmonary inflammation and fibrosis. Thus, here we investigated the effects of the GSK-3 inhibitor 3-(2,4-dichlorophenyl)-4-(1-methyl-1Hindol-3-yl)- 1H-pyrrole-2,5-dione (SB216763) on a BLMinduced lung fibrosis model in mice. SB216763 prevented lung inflammation and the subsequent fibrosis when coad-ministered with BLM. Bronchoalveolar lavage fluid analysis of mice treated with BLM plus SB216763 revealed a significant reduction in BLM-induced alveolitis. Furthermore, SB216763 treatment was associated with a significantly lower production of inflammatory cytokines by macrophages. BLM-treated mice that received SB216763 developed alveolar epithelial cell damage and pulmonary fibrosis to a significantly lower extent compared with BLM-treated controls. These findings suggest that GSK-3 inhibition has a protective effect on lung fibrosis induced by BLM and candidate GSK-3 as a potential therapeutic target for preventing pulmonary fibrosis.",
author = "Carmela Gurrieri and Francesco Piazza and Marianna Gnoato and Barbara Montini and Lucia Biasutto and Cristina Gattazzo and Enrico Brunetta and Anna Cabrelle and Francesco Cinetto and Raffaele Niero and Monica Facco and Spiridione Garbisa and Fiorella Calabrese and Gianpietro Semenzato and Carlo Agostini",
year = "2010",
month = "3",
doi = "10.1124/jpet.109.153049",
language = "English",
volume = "332",
pages = "785--794",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - 3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis

AU - Gurrieri, Carmela

AU - Piazza, Francesco

AU - Gnoato, Marianna

AU - Montini, Barbara

AU - Biasutto, Lucia

AU - Gattazzo, Cristina

AU - Brunetta, Enrico

AU - Cabrelle, Anna

AU - Cinetto, Francesco

AU - Niero, Raffaele

AU - Facco, Monica

AU - Garbisa, Spiridione

AU - Calabrese, Fiorella

AU - Semenzato, Gianpietro

AU - Agostini, Carlo

PY - 2010/3

Y1 - 2010/3

N2 - Glycogen synthase kinase (GSK)-3 modulates the production of inflammatory cytokines. Because bleomycin (BLM) causes lung injury, which is characterized by an inflammatory response followed by a fibrotic degeneration, we postulated that blocking GSK-3 activity with a specific inhibitor could affect the inflammatory and profibrotic cytokine network generated in the BLM-induced process of pulmonary inflammation and fibrosis. Thus, here we investigated the effects of the GSK-3 inhibitor 3-(2,4-dichlorophenyl)-4-(1-methyl-1Hindol-3-yl)- 1H-pyrrole-2,5-dione (SB216763) on a BLMinduced lung fibrosis model in mice. SB216763 prevented lung inflammation and the subsequent fibrosis when coad-ministered with BLM. Bronchoalveolar lavage fluid analysis of mice treated with BLM plus SB216763 revealed a significant reduction in BLM-induced alveolitis. Furthermore, SB216763 treatment was associated with a significantly lower production of inflammatory cytokines by macrophages. BLM-treated mice that received SB216763 developed alveolar epithelial cell damage and pulmonary fibrosis to a significantly lower extent compared with BLM-treated controls. These findings suggest that GSK-3 inhibition has a protective effect on lung fibrosis induced by BLM and candidate GSK-3 as a potential therapeutic target for preventing pulmonary fibrosis.

AB - Glycogen synthase kinase (GSK)-3 modulates the production of inflammatory cytokines. Because bleomycin (BLM) causes lung injury, which is characterized by an inflammatory response followed by a fibrotic degeneration, we postulated that blocking GSK-3 activity with a specific inhibitor could affect the inflammatory and profibrotic cytokine network generated in the BLM-induced process of pulmonary inflammation and fibrosis. Thus, here we investigated the effects of the GSK-3 inhibitor 3-(2,4-dichlorophenyl)-4-(1-methyl-1Hindol-3-yl)- 1H-pyrrole-2,5-dione (SB216763) on a BLMinduced lung fibrosis model in mice. SB216763 prevented lung inflammation and the subsequent fibrosis when coad-ministered with BLM. Bronchoalveolar lavage fluid analysis of mice treated with BLM plus SB216763 revealed a significant reduction in BLM-induced alveolitis. Furthermore, SB216763 treatment was associated with a significantly lower production of inflammatory cytokines by macrophages. BLM-treated mice that received SB216763 developed alveolar epithelial cell damage and pulmonary fibrosis to a significantly lower extent compared with BLM-treated controls. These findings suggest that GSK-3 inhibition has a protective effect on lung fibrosis induced by BLM and candidate GSK-3 as a potential therapeutic target for preventing pulmonary fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=77249158055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249158055&partnerID=8YFLogxK

U2 - 10.1124/jpet.109.153049

DO - 10.1124/jpet.109.153049

M3 - Article

C2 - 19959748

AN - SCOPUS:77249158055

VL - 332

SP - 785

EP - 794

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -